• 💪 Hello, please SIGN-UP FOR A FREE account and become a member of our community!
    You will then be able to start threads, post comments and send messages to other members. Thanks!
  • 🔥 Kits4Less.com #1 MOST LAB-TESTED SOURCE — 25% OFF YOUR FIRST ORDER! 🔥

Tesamorelin Solidifying

MadWorldUSA

Registered
Joined
Nov 4, 2024
Messages
7
Reaction score
0
SB Labs
Need some help. I bought 6 vials of 10 mg Tesamorelin.
Every single vial has turned to hard gel after I reconstituted it. Has anyone ever sucessfully cycled tesamorelin? Who did you purchase from. What are the reconstitution instructions?
I've never had this happen to me with a peptide before and it cost me $200. Can anyone help me learn from my mistake?

(Also not interested in taking HGH.)


From Google"
In essence, a reconstituted peptide can turn to a solid, or precipitate, under various conditions that negatively impact its stability and solubility.
Here's a breakdown of the most common factors that can lead to this:
Factors influencing peptide instability and solidification
  • Peptide Concentration: Higher concentrations can increase the likelihood of peptide molecules interacting and forming aggregates that can eventually precipitate out of solution.
  • pH of the Solution: The pH can significantly affect the charge of the peptide, influencing its solubility. Deviation from the optimal pH range can decrease solubility and lead to precipitation.
  • Temperature: Elevated temperatures can increase the kinetic energy of the peptide molecules, promoting aggregation and precipitation.
  • Presence of Impurities: Impurities like solvents, salts, or other excipients can interact with the peptide, affecting its solubility and potentially promoting aggregation.
  • Freeze-thaw Cycles: Repeated freezing and thawing can cause peptides to degrade and aggregate, leading to precipitation.
  • Amino Acid Sequence and Composition: Certain amino acids (like those containing cysteine, methionine, or tryptophan) are more prone to oxidation and can lead to instability and precipitation. Peptides with a high content of hydrophobic residues may also be more susceptible to aggregation.
  • Exposure to Light or Oxygen: Light-sensitive residues like Trp, Tyr, and Phe are vulnerable to photodegradation, potentially leading to aggregation and precipitation. Oxidative reactions, particularly for residues like Cys and Met, can also contribute to this phenomenon.
  • Physical Stressors: Agitation or shaking during handling can also promote aggregation and subsequent precipitation.
Recommendations to minimize or prevent solidification
  • Follow Manufacturer's Guidelines: Adhere to the recommended solvent, pH, and storage temperature specified for your specific peptide.
  • Store Peptides in Lyophilized Form: Peptides in lyophilized (freeze-dried) form are generally more stable than in solution, especially for long-term storage.
  • Use Sterile Buffers: Reconstitute peptides in sterile buffers at the recommended pH (often between 5 and 6) to prolong stability.
  • Freeze Solutions for Longer Storage: If storing for extended periods, freezing the reconstituted peptide solution at -20°C or colder is generally recommended.
  • Aliquot to Avoid Freeze-Thaw Cycles: To minimize the impact of freeze-thaw, aliquot the peptide solution into smaller portions before freezing.
  • Minimize Exposure to Air and Light: Store peptides in sealed containers under an inert atmosphere (e.g., nitrogen or argon) and in dark conditions.
By carefully considering and managing these factors, you can significantly reduce the chances of a reconstituted peptide turning to a solid and maintain its stability and biological activity for longer durations.

Tesamorelin, commonly known by its brand name Egrifta SV, is provided as a lyophilized powder and needs to be reconstituted with a specific solvent before being injected subcutaneously.
The solvent used for tesamorelin reconstitution is Sterile Water for Injection.
When preparing the injection, only the diluent (sterile water for injection) provided with the Egrifta SV kit should be used to reconstitute the tesamorelin powder. Using other liquids may damage the medication.
It's important to note that Egrifta SV requires daily reconstitution, and any unused reconstituted solution should be discarded immediately. Egrifta WR, another formulation of tesamorelin, only requires weekly reconstitution and has different storage instructions after mixing. Always consult the specific product instructions and your healthcare provider for proper reconstitution and administration procedures for your specific formulation of tesamorelin.

Here's a breakdown of the solvents used for each formulation:
  • Egrifta SV: Is reconstituted with Sterile Water for Injection. This formulation requires daily reconstitution and administration.
  • Egrifta WR: Is reconstituted with Bacteriostatic Water for Injection, USP, which contains benzyl alcohol as a preservative. This formulation is injected daily, but only needs weekly reconstitution.
Important Notes:
  • Always use the diluent (solvent) provided with the specific tesamorelin product (Egrifta SV or Egrifta WR).
  • Reconstituted tesamorelin should be used immediately. Do not store or refrigerate the reconstituted solution unless specifically instructed by the manufacturer and your healthcare provider.
  • Consult the specific instructions for use provided with your tesamorelin kit or your healthcare provider for detailed reconstitution and administration procedures.
When tesamorelin is reconstituted with the appropriate diluent, the solution should be clear and colorless, without any particulate matter. If the liquid turns cloudy, colored, or contains solid particles, it indicates that the medication has been damaged or is no longer suitable for injection.
  • Possible reasons for damage:
    • Improper storage: Reconstituted tesamorelin is sensitive to temperature and can degrade if not stored correctly. Egrifta SV, for example, should be used immediately after reconstitution and should not be refrigerated or frozen. Egrifta WR, however, can be stored at room temperature (20°C to 25°C or 68°F to 77°F) for up to 7 days after reconstitution.
    • Expired medication: Always check the expiration date on the vial and carton. Do not use tesamorelin past its expiration date.
    • Contamination during reconstitution: Ensure proper aseptic technique when reconstituting the medication.
 
This seems to be more common with AOD, but I would try letting it sit at room temp and see if it comes back to liquid. If not, it could be related to the ph of your bac water. Are you using Hospira bac water or a diff brand?
 

How should I store Egrifta WR?​

You will be given a Medication Box and an Injection Box when you get your Egrifta WR prescription from the pharmacy. Protect from light and do not freeze. Store the Egrifta WR vials in the Medication Box at at room temperature, between 68 F and 77 F (20 C and 25 C). Store the Bacteriostatic Water for Injection, syringes, needles and alcohol swabs that come in the Injection Box at room temperature, between 68 F and 77 F (20 C and 25 C).

Once mixed, the vial will contain enough medicine for 7 doses. Keep the Egrifta WR vial in your Medication Box, at room temperature between 68 F and 77 F (20 C and 25 C). Throw away any unused Egrifta WR vial 7 days after mixing. Throw away any Bacteriostatic Water for Injection left in the bottle 28 days after first use.

So I stored in the refridgerator, maybe that is the problem?
 
Store the medication box containing the tesamorelin injection vials in the refrigerator. Do not freeze. Store the box containing the provided liquid, needles, and syringes at room temperature away from light, excess heat, and moisture (not in the bathroom). Keep each box tightly closed and out of reach of children.
 

Latest threads

Back
Top